#$%^&*AU2020203110A120200611.pdf#####ABSTRACT In some aspects, the invention teaches pharmaceutical compositions that include a TGFp ligand binding domain of a TGF-P type 11 receptor, and methods of using a TGFp ligand binding domain of a TGF-P type 11 receptor to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGFp ligand binding domain of a TGF-P type 11 receptor to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodelling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signalling, diseases associated with excessive GDF15 signalling, and diseases associated with excessive PAl-1 signalling. The invention further provides methods of using a TGFp ligand binding domain of a TGF-P type 11 receptor to reduce right ventricular systolic pressure in a subject.
